What is the clinical evidence from this study?

Study design: Observational. Population: Pediatric cardiomyopathy. Intervention: Biallelic truncating mutations in ALPK3. Primary outcome: Severe hypertrophic and/or dilated cardiomyopathy.

What does this research mean for the field?

Biallelic truncating mutations in ALPK3 cause severe, early-onset hypertrophic and/or dilated cardiomyopathy, frequently resulting in fatal heart failure in the neonatal period. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

To identify the causal genetic variants responsible for severe, early-onset cardiomyopathy in pediatric patients.

August 31, 2026Journal of the American College of CardiologyOpen Access

Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Key result

Biallelic ALPK3 truncating mutations linked to severe early-onset cardiomyopathy, fatal in 3 of 5 neonates.

Why the study?

The molecular mechanism underlying pediatric cardiomyopathy remains elusive in a substantial proportion of cases, prompting the search for new causative genes.

Design

Homozygosity mapping, whole-exome sequencing, and candidate gene screening

Authors

RARowida AlmomaniJordan University of Science and Technology JVJudith M.A. VerhagenErasmus MC JHJohanna C. HerkertUniversity Medical Center Groningen

Discussion

Member takes

Implication

Genetic analysis uncovers biallelic truncating mutations in ALPK3 in pediatric cardiomyopathy, highlighting a critical role for alpha-kinase 3 in early cardiac structure and function.

Key Points

To identify the causal genetic variants responsible for severe, early-onset cardiomyopathy in pediatric patients.
Performed genetic mapping and whole-exome sequencing in pediatric cohorts exhibiting severe cardiomyopathy.
Evaluated functional and structural consequences of identified homozygous and compound heterozygous variants in the ALPK3 gene.
Biallelic truncating mutations in ALPK3 were identified as the underlying cause of severe, familial early-onset cardiomyopathy.
Loss of functional alpha-kinase 3 protein disrupted sarcomeric organization and normal cardiac muscle architecture, leading to severe pediatric cardiac dysfunction.

Study Design

Type

Observational

PICO

Population

Patients with idiopathic pediatric cardiomyopathy and their family members undergoing genetic screening.

Exposure / Comparator

Biallelic truncating mutations in ALPK3

Primary Outcome

Severe hypertrophic and/or dilated cardiomyopathy

Cite This Study

Almomani et al. (2016) conducted an observational in Pediatric cardiomyopathy. Biallelic truncating mutations in ALPK3 was evaluated on Severe hypertrophic and/or dilated cardiomyopathy. Biallelic truncating mutations in ALPK3 cause severe, early-onset hypertrophic and/or dilated cardiomyopathy, with 3 of 5 identified patients dying from heart failure within the first week of life.

synapsesocial.com/papers/6a95efba300fdfe30a98b4f4 https://doi.org/10.1016/j.jacc.2015.10.093

View Full Paper

Ask AI

Bookmark

Implication

Genetic analysis uncovers biallelic truncating mutations in ALPK3 in pediatric cardiomyopathy, highlighting a critical role for alpha-kinase 3 in early cardiac structure and function.

Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Study Design

PICO

Cite This Study

Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Study Design

PICO

Cite This Study

Also Consider

Also Consider